136 related articles for article (PubMed ID: 8464176)
1. [Effect of TUDCA for cholestatic reaction due to serum in patient with primary biliary cirrhosis].
Kuroda H; Satoh N; Tajima J; Sakakibara H; Nakazawa M; Hirose M
Nihon Shokakibyo Gakkai Zasshi; 1993 Feb; 90(2):190. PubMed ID: 8464176
[No Abstract] [Full Text] [Related]
2. Ursodeoxycholic and tauro-ursodeoxycholic acids for the treatment of primary biliary cirrhosis: a pilot crossover study.
Larghi A; Crosignani A; Battezzati PM; De Valle G; Allocca M; Invernizzi P; Zuin M; Podda M
Aliment Pharmacol Ther; 1997 Apr; 11(2):409-14. PubMed ID: 9146783
[TBL] [Abstract][Full Text] [Related]
3. TUDCA prevents cholestasis and canalicular damage induced by ischemia-reperfusion injury in the rat, modulating PKCalpha-ezrin pathway.
Baiocchi L; Tisone G; Russo MA; Longhi C; Palmieri G; Volpe A; Almerighi C; Telesca C; Carbone M; Toti L; De Leonardis F; Angelico M
Transpl Int; 2008 Aug; 21(8):792-800. PubMed ID: 18435680
[TBL] [Abstract][Full Text] [Related]
4. Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver.
Beuers U; Bilzer M; Chittattu A; Kullak-Ublick GA; Keppler D; Paumgartner G; Dombrowski F
Hepatology; 2001 May; 33(5):1206-16. PubMed ID: 11343250
[TBL] [Abstract][Full Text] [Related]
5. Tauroursodeoxycholic acid stimulates hepatocellular exocytosis and mobilizes extracellular Ca++ mechanisms defective in cholestasis.
Beuers U; Nathanson MH; Isales CM; Boyer JL
J Clin Invest; 1993 Dec; 92(6):2984-93. PubMed ID: 8254052
[TBL] [Abstract][Full Text] [Related]
6. Modulation of the Unfolded Protein Response by Tauroursodeoxycholic Acid Counteracts Apoptotic Cell Death and Fibrosis in a Mouse Model for Secondary Biliary Liver Fibrosis.
Paridaens A; Raevens S; Devisscher L; Bogaerts E; Verhelst X; Hoorens A; Van Vlierberghe H; van Grunsven LA; Geerts A; Colle I
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28117681
[TBL] [Abstract][Full Text] [Related]
7. Tauroursodeoxycholic acid reduces bile acid-induced apoptosis by modulation of AP-1.
Pusl T; Vennegeerts T; Wimmer R; Denk GU; Beuers U; Rust C
Biochem Biophys Res Commun; 2008 Feb; 367(1):208-12. PubMed ID: 18164257
[TBL] [Abstract][Full Text] [Related]
8. Taurohyodeoxycholic acid protects against taurochenodeoxycholic acid-induced cholestasis in the rat.
Roda A; Piazza F; Baraldini M; Speroni E; Guerra MC; Cerré C; Cantelli Forti G
Hepatology; 1998 Feb; 27(2):520-5. PubMed ID: 9462652
[TBL] [Abstract][Full Text] [Related]
9. Tauroursodeoxycholic acid exerts anticholestatic effects by a cooperative cPKC alpha-/PKA-dependent mechanism in rat liver.
Wimmer R; Hohenester S; Pusl T; Denk GU; Rust C; Beuers U
Gut; 2008 Oct; 57(10):1448-54. PubMed ID: 18583398
[TBL] [Abstract][Full Text] [Related]
10. Effect of sodium tauroursodeoxycholate (UR-906) on liver dysfunction in bile duct-ligated rats.
Ishizaki K; Kinbara S; Miyazawa N; Takeuchi Y; Hirabayashi N; Kasai H; Araki T
Eur J Pharmacol; 1997 Aug; 333(2-3):207-13. PubMed ID: 9314037
[TBL] [Abstract][Full Text] [Related]
11. [Modulation by tauroursodeoxycholic acid of proliferation of the rat ischemic liver hepatocytes].
Danchenko EO
Vopr Med Khim; 2001; 47(4):405-10. PubMed ID: 11693028
[TBL] [Abstract][Full Text] [Related]
12. Tauroursodeoxycholic acid activates protein kinase C in isolated rat hepatocytes.
Beuers U; Throckmorton DC; Anderson MS; Isales CM; Thasler W; Kullak-Ublick GA; Sauter G; Koebe HG; Paumgartner G; Boyer JL
Gastroenterology; 1996 May; 110(5):1553-63. PubMed ID: 8613063
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of cholestatic liver disease].
Pleşa A
Rev Med Chir Soc Med Nat Iasi; 2003; 107(4):733-6. PubMed ID: 14756010
[TBL] [Abstract][Full Text] [Related]
14. New therapeutical indications of ursodeoxycholic acid.
Copaci I; Micu L; Iliescu L; Voiculescu M
Rom J Gastroenterol; 2005 Sep; 14(3):259-66. PubMed ID: 16200237
[TBL] [Abstract][Full Text] [Related]
15. Hepatoprotection in ethinylestradiol-treated rats is provided by tauroursodeoxycholic acid, but not by ursodeoxycholic acid.
Azer SA; Canfield PJ; Stacey NH
J Gastroenterol Hepatol; 1995; 10(3):261-9. PubMed ID: 7548801
[TBL] [Abstract][Full Text] [Related]
16. Effect of taurohyodeoxycholic acid on biliary lipid secretion in man: preliminary report.
Loria P; Bozzoli M; Angelico M; Bertolotti M; Carubbi F; Concari M; Baiocchi L; Nistri A; Della Guardia P; Romani M; Carulli N
Ital J Gastroenterol; 1996 Sep; 28(7):391-2. PubMed ID: 8937941
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of cholestatic liver diseases].
Gatzen M; Pausch J
Med Klin (Munich); 2002 Mar; 97(3):152-9. PubMed ID: 11957790
[TBL] [Abstract][Full Text] [Related]
18. Choleretic and cholestatic effects of infused bile salts in the rat.
Drew R; Priestly BG
Experientia; 1979 Jun; 35(6):809-11. PubMed ID: 467601
[TBL] [Abstract][Full Text] [Related]
19. One-year pilot study on tauroursodeoxycholic acid as an adjuvant treatment after liver transplantation.
Angelico M; Tisone G; Baiocchi L; Palmieri G; Pisani F; Negrini S; Anselmo A; Vennarecci G; Casciani CU
Ital J Gastroenterol Hepatol; 1999; 31(6):462-8. PubMed ID: 10575563
[TBL] [Abstract][Full Text] [Related]
20. Serum bile acids in primary biliary cirrhosis.
Murphy GM; Ross A; Billing BH
Gut; 1972 Mar; 13(3):201-6. PubMed ID: 5024725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
